MinervaX is engaged in clinical development of a Group B Streptococcal vaccine targeting pregnant women for the prevention of life-threatening infections in newborns. So far the vaccine has been dosed to 240 healthy adult women. The vaccine has proven safe, highly immunogenic and giving rise to functionally active antibodies.

https://www.minervax.com/